4.7 Review

Dysbiosis and the immune system

Journal

NATURE REVIEWS IMMUNOLOGY
Volume 17, Issue 4, Pages 219-232

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/nri.2017.7

Keywords

-

Categories

Funding

  1. European Molecular Biology Organization
  2. Boehringer Ingelheim Fonds
  3. Israel
  4. Leona M. and Harry B. Helmsley Charitable Trust
  5. Gurwin Family Fund for Scientific Research
  6. Crown Endowment Fund for Immunological Research
  7. estate of Jack Gitlitz
  8. estate of Lydia Hershkovich
  9. Benoziyo Endowment Fund
  10. Adelis Foundation
  11. Pacific Palisades, California, USA
  12. Canada
  13. Centre National de la Recherche Scientifique
  14. estate of Samuel and Alwyn J. Weber
  15. California, USA
  16. European Research Council
  17. German-Israel Binational foundation
  18. Israel Science Foundation
  19. Minerva Foundation
  20. Rising Tide Foundation
  21. Alon Foundation

Ask authors/readers for more resources

Throughout the past century, we have seen the emergence of a large number of multifactorial diseases, including inflammatory, autoimmune, metabolic, neoplastic and neurodegenerative diseases, many of which have been recently associated with intestinal dysbiosis-that is, compositional and functional alterations of the gut microbiome. In linking the pathogenesis of common diseases to dysbiosis, the microbiome field is challenged to decipher the mechanisms involved in the de novo generation and the persistence of dysbiotic microbiome configurations, and to differentiate causal host-microbiome associations from secondary microbial changes that accompany disease course. In this Review, we categorize dysbiosis in conceptual terms and provide an overview of immunological associations; the causes and consequences of bacterial dysbiosis, and their involvement in the molecular aetiology of common diseases; and implications for the rational design of new therapeutic approaches. A molecularlevel understanding of the origins of dysbiosis, its endogenous and environmental regulatory processes, and its downstream effects may enable us to develop microbiome-targeting therapies for a multitude of common immune-mediated diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available